Compugen News

Merck Discontinues Testing of Experimental Skin Cancer Combo Therapy

Seeking Alpha47minutes ago

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

PR NewswireMay 6 19:00

Investors Don't See Light At End Of Compugen Ltd.'s (NASDAQ:CGEN) Tunnel And Push Stock Down 26%

Compugen Ltd. (NASDAQ:CGEN) shareholders that were waiting for something to happen have been dealt a blow with a 26% share price drop in the last month.

Simply Wall StApr 28 20:24

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer With Liver Metastases at ASCO 2024

HOLON, Israel, April 25, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced

PR NewswireApr 25 19:00

Compugen Reports Publication Of Paper In Cancer Immunology Research Demonstrating Therapeutic Potential Of COM503

Compugen Reports Publication Of Paper In Cancer Immunology Research Demonstrating Therapeutic Potential Of COM503

BenzingaApr 10 19:02

Compugen to Participate in Two Upcoming Investor Conferences

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

PR NewswireApr 3 19:00

Truist Financial Reaffirms Their Buy Rating on Compugen (CGEN)

TipRanksMar 15 19:08

Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) Is a Great Choice

Yahoo FinanceMar 13 00:00

Compugen Selected for Two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

PR NewswireMar 11 19:00

Compugen Is Maintained at Buy by Truist Securities

Compugen Is Maintained at Buy by Truist Securities

Dow JonesMar 8 22:25

Truist Securities Maintains Buy on Compugen, Raises Price Target to $5

Truist Securities analyst Asthika Goonewardene maintains Compugen (NASDAQ:CGEN) with a Buy and raises the price target from $4 to $5.

BenzingaMar 8 22:15

Compugen Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/08/2024 89.39% Truist Securities $4 → $5 Maintains Buy 12/19/2023 51.52% Stifel $3 → $4 Maintains Buy 0

BenzingaMar 8 22:13

Analysts Offer Insights on Healthcare Companies: Cigna (CI), Compugen (CGEN) and OrthoPediatrics (KIDS)

TipRanksMar 8 20:20

Compugen Ltd. (NASDAQ:CGEN) Held Back By Insufficient Growth Even After Shares Climb 26%

Compugen Ltd. (NASDAQ:CGEN) shares have continued their recent momentum with a 26% gain in the last month alone. The annual gain comes to 258% following the latest surge, making investors sit up an

Simply Wall StMar 8 18:54

Compugen Ltd. (NASDAQ:CGEN) Q4 2023 Earnings Call Transcript

Yahoo FinanceMar 7 22:41

Buy Rating Justified by Compugen's Positive Clinical Outlook and Financial Stability

TipRanksMar 7 12:18

Earnings Call: Compugen Reports Solid 2023 Results, Plans for Future Growth

InvestingMar 7 02:04

Compugen to Present Data Reflecting Its Diversified Immuno-Oncology Pipeline at AACR 2024

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

PR NewswireMar 6 20:00

Earnings Call Summary | Compugen(CGEN.US) Q4 2023 Earnings Conference

The following is a summary of the Compugen Ltd. (CGEN) Q4 2023 Earnings Call Transcript:Financial Performance:Compugen had approximately $51.1 million in cash, cash equivalents, restricted cash, and c

Futu NewsMar 6 04:05 · Conference Call

Regenxbio, Quoin Pharmaceuticals, Renalytix Among Healthcare Movers

Seeking AlphaMar 5 23:02